JP2019517478A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517478A5
JP2019517478A5 JP2018562106A JP2018562106A JP2019517478A5 JP 2019517478 A5 JP2019517478 A5 JP 2019517478A5 JP 2018562106 A JP2018562106 A JP 2018562106A JP 2018562106 A JP2018562106 A JP 2018562106A JP 2019517478 A5 JP2019517478 A5 JP 2019517478A5
Authority
JP
Japan
Prior art keywords
optionally substituted
heteroaryl
aryl
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034564 external-priority patent/WO2017205684A1/en
Publication of JP2019517478A publication Critical patent/JP2019517478A/ja
Publication of JP2019517478A5 publication Critical patent/JP2019517478A5/ja
Pending legal-status Critical Current

Links

JP2018562106A 2016-05-25 2017-05-25 ファルネソイドxレセプター(fxr)モジュレーターとの併用療法 Pending JP2019517478A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
US62/341,482 2016-05-25
US62/341,487 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (2)

Publication Number Publication Date
JP2019517478A JP2019517478A (ja) 2019-06-24
JP2019517478A5 true JP2019517478A5 (cg-RX-API-DMAC10.html) 2020-07-02

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562106A Pending JP2019517478A (ja) 2016-05-25 2017-05-25 ファルネソイドxレセプター(fxr)モジュレーターとの併用療法

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Similar Documents

Publication Publication Date Title
RU2018145776A (ru) Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr)
US12559473B2 (en) Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
US20260098036A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US11459312B2 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11591311B2 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
JP2024514010A5 (cg-RX-API-DMAC10.html)
US11524944B2 (en) 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
RU2011116230A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP7201817B2 (ja) 3,3-ジフルオロアリルアミンまたはその塩およびこれらを含有する薬学的組成物
EA032028B1 (ru) СТИМУЛЯТОРЫ рГЦ
CA2959757A1 (en) Pyrazole derivatives as sgc stimulators
JP2017527604A (ja) sGC刺激剤
KR102788118B1 (ko) 신규한 트리아졸론 유도체 또는 그의 염, 및 그를 포함하는 제약 조성물
JP2018512408A5 (cg-RX-API-DMAC10.html)
JP2021518379A5 (cg-RX-API-DMAC10.html)
JP2020526549A5 (cg-RX-API-DMAC10.html)
TW202208359A (zh) 新穎二醯基甘油酯o-醯基轉移酶2抑制劑
RU2016111522A (ru) Фармацевтические соединения
JP2014527997A5 (cg-RX-API-DMAC10.html)
JP2023509186A5 (cg-RX-API-DMAC10.html)
TW201803866A (zh) 新穎經取代之苯并咪唑,其製備方法,包含其之醫藥製劑及其用於製備藥劑之用途
JP2014525929A5 (cg-RX-API-DMAC10.html)
JP2019515939A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
RU2023127043A (ru) Фармацевтические соединения в качестве ингибиторов убиквитинспецифической протеазы 19 (usp19)
RU2024111199A (ru) Ингибиторы fgfr и способы их применения